Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 02 December 2015 | By Michael Mezher
The US Food and Drug Administration (FDA) has released new recommendations for blood establishments to implement additional screening measures during Ebola virus outbreaks.
Since the outbreak began in 2014, the World Health Organization (WHO) estimates that there have been more than 28,000 cases of Ebola, resulting in 11,314 deaths.
The outbreak has proven particularly difficult for health authorities to quell in Guinea, Sierra Leone and Liberia. In November, WHO declared that Ebola transmission had ended in Sierra Leone, and Guinea discharged its last known Ebola patient, a baby girl, from the hospital.
However, in the same month three new cases of Ebola were reported in Liberia, where WHO has twice declared transmission had stopped, in May and September 2015.
While WHO has spearheaded the international response to the outbreak, several US agencies including FDA, the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) have also played a role in the response to the epidemic.
For its part, FDA has issued 10 emergency use authorizations (EUAs) for products to treat or diagnose Ebola. The agency has also granted orphan designation to many products in development to treat Ebola, and says it has deployed "at least 12 FDA employees … to West Africa as part of the Public Health Service's team."
FDA says its new draft guidance, Recommendations for Assessment of Blood Donor Suitability, Donor Deferral and Blood Product Management in Response to Ebola Virus, is intended to be used when there is an ongoing Ebola outbreak with "widespread transmission in at least one country."
While Ebola symptoms typically present within 21 days of infection, recent analyses have demonstrated that some patients may not become symptomatic till much later. Additionally, scientists have discovered that infectious Ebola virus and viral RNA can remain present in certain parts of the body and bodily fluids for months after symptoms have resolved.
Other reports have signaled the possibility of asymptomatic infection, which could in theory lead to infection of others.
For these reasons, FDA is recommending blood establishments implement additional screening measures when the CDC declares there is widespread Ebola transmission in one or more countries.
Facilities that collect blood or blood components are instructed to ask potential donors about any history of Ebola infection, travel or residence in any country effected by an outbreak or contact with infected persons in the previous eight weeks.
FDA says that blood establishments should indefinitely defer donors who have had Ebola virus. The agency also recommends deferring donation by eight weeks for any donors who traveled to or lived in an effected country, or were in close contact with an infected individual.
The guidance goes on to advise blood establishments on what actions to take in case blood is collected from an at-risk or infected donor, including instructions on sample destruction and when to report a biological product deviation (BPD) to FDA.
WHO has identified convalescent plasma, or plasma gathered from recovered Ebola patients, as a potential treatment for the disease.
While some uncontrolled studies have been conducted to investigate the use of convalescent plasma to treat Ebola, such uses are still considered investigational by FDA and WHO. Thus, FDA says that any establishments that intend to "collect or distribute convalescent plasma intended for transfusion in the United States must submit an investigational new drug application." Similarly, device sponsors are expected to follow investigational device regulations for any new device to be used for such purposes.
FDA
Tags: Ebola
Regulatory Focus newsletters
All the biggest regulatory news and happenings.